Skip to main content
. 2016 Oct 31;7(4):621–639. doi: 10.1007/s13300-016-0208-5

Fig. 1.

Fig. 1

Pathophysiologic abnormalities targeted by currently available antihyperglycemic medications. DPP4i dipeptidyl peptidase 4 inhibitor, GLP1 RA glucagon-like peptide 1 receptor agonist, HGP hepatic glucose production, MET metformin, SGLT2i sodium glucose cotransporter 2 inhibitor, TZD thiazolidinedione. “From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus”. American Diabetes Association, 2009. Copyright and all rights reserved. Material from this publication has been used with the permission of the American Diabetes Association